Personalized targeted therapy for advanced pancreatic and breast cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This trial tests a new medicine that targets cancer cells with specific proteins, to see if it can stop the growth of advanced pancreatic and breast cancer when other treatments have stopped working. It is an umbrella study, which means different protein-matched drugs are tested for different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced (unresectable or spread) pancreatic or breast cancer that has continued to grow despite at least two previous treatments.
- You can carry out daily activities fully (ECOG 0 or 1), with a life expectancy of at least 3 months.
- You have at least one measurable tumor outside the brain.
- Your blood counts, liver, kidney, and heart function are within acceptable limits, and if you can become pregnant, you agree to use highly effective birth control.
- You must not have had certain other cancers, severe lung disease, active serious infections, or unstable heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Hear when a new Advanced or Metastatic Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.